D
David Hogg
Researcher at Princess Margaret Cancer Centre
Publications - 46
Citations - 7730
David Hogg is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ipilimumab & Nivolumab. The author has an hindex of 19, co-authored 46 publications receiving 5610 citations. Previous affiliations of David Hogg include University Health Network & University of Toronto.
Papers
More filters
Journal ArticleDOI
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Piotr Rutkowski,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,John Wagstaff,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,Reinhard Dummer,Andrew F. Hill,David Hogg,John B. A. G. Haanen,Matteo S. Carlino,Oliver Bechter,Michele Maio,Ivan Marquez-Rodas,Massimo Guidoboni,Grant A. McArthur,Céleste Lebbé,Paolo A. Ascierto,Georgina V. Long,Jonathan Cebon,Jeffrey A. Sosman,Michael A. Postow,Margaret K. Callahan,Dana Walker,Linda Rollin,Rafia Bhore,F. Stephen Hodi,James Larkin,James Larkin +33 more
TL;DR: Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with n ivolumAB alone than with ipil optimumab alone.
Journal ArticleDOI
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
F.S. Hodi,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Charles Lance Cowey,Christopher D. Lao,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Pier Francesco Ferrucci,Michael Smylie,Andrew F. Hill,David Hogg,Ivan Marquez-Rodas,Joel Jiang,Jasmine I. Rizzo,James Larkin,Jedd D. Wolchok,Jedd D. Wolchok +19 more
TL;DR: The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018.
Journal ArticleDOI
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur,Paul B. Chapman,Caroline Robert,James Larkin,John B. A. G. Haanen,Reinhard Dummer,Antoni Ribas,David Hogg,Omid Hamid,Paolo A. Ascierto,Claus Garbe,Alessandro Testori,Michele Maio,Paul Lorigan,C. Lebbé,Thomas Jouary,Dirk Schadendorf,Stephen J O'Day,John M. Kirkwood,Alexander M.M. Eggermont,Brigitte Dréno,Jeffrey A. Sosman,Keith T. Flaherty,Ming Yin,Ivor Caro,Suzanne Cheng,Kerstin Trunzer,Axel Hauschild +27 more
TL;DR: An extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF (V600K) mutation subgroups is presented, finding that overall survival and progression-free survival was significantly longer in the vemurafenib group than in the dacarbazine group.
Journal ArticleDOI
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies,Philippe Saiag,Caroline Robert,Jean-Jacques Grob,Keith T. Flaherty,Ana Arance,Vanna Chiarion-Sileni,Luc Thomas,Thierry Lesimple,Laurent Mortier,Stergios J. Moschos,David Hogg,Ivan Marquez-Rodas,Michele Del Vecchio,Céleste Lebbé,Nicolas Meyer,Ying Zhang,Yingjie Huang,Bijoyesh Mookerjee,Georgina V. Long +19 more
TL;DR: Results from the phase 2 COMBI-MB trial provide evidence of clinical benefit with dabrafenib plus trametinib and support the need for additional research to further improve outcomes in patients with melanoma brain metastases.
Journal ArticleDOI
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer,Dirk Schadendorf,Paolo A. Ascierto,Ana Arance,Caroline Dutriaux,Anna Maria Di Giacomo,Piotr Rutkowski,Michele Del Vecchio,Ralf Gutzmer,Mario Mandalà,Luc Thomas,Lev V. Demidov,Claus Garbe,David Hogg,Gabriella Liszkay,Paola Queirolo,Ernesto Wasserman,James Ford,Marine Weill,L. Andres Sirulnik,Valentine Jehl,Viviana Bozón,Georgina V. Long,Keith T. Flaherty +23 more
TL;DR: Binimetinib improved progression-free survival compared with dacarbazine and was tolerable, and might represent a new treatment option for patients with NRAS-mutant melanoma after failure of immunotherapy.